An Innovative Inhibitor with a New Chemical Moiety Aimed at Biliverdin IXβ Reductase for Thrombocytopenia and Resilient against Cellular Degradation

• Main Authors: Hoe-Myung Jung (Author), Jung-Hye Ha (Author), Mark Vincent C. dela Cerna (Author), Joseph A. Burlison (Author), Joonhyeok Choi (Author), Bo-Ram Kim (Author), Jeong Kyu Bang (Author), Kyoung-Seok Ryu (Author), Donghan Lee (Author)
• Format: Book
• Published: MDPI AG, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Biliverdin IXβ reductase (BLVRB) has emerged as a promising therapeutic target for thrombocytopenia due to its involvement in reactive oxygen species (ROS) mechanisms. During the pursuit of inhibitors targeting BLVRB, olsalazine (OSA) became apparent as one of the most potent candidates. However, th...